Research Analysts Issue Forecasts for ONCY FY2024 Earnings

Oncolytics Biotech Inc. (NASDAQ:ONCY) – Raymond James reduced their FY2024 EPS estimates for shares of Oncolytics Biotech in a research report issued to clients and investors on Tuesday, November 12th. Raymond James analyst R. Sarugaser now anticipates that the company will post earnings per share of ($0.32) for the year, down from their previous estimate of ($0.28). The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.29) per share. Raymond James also issued estimates for Oncolytics Biotech’s Q4 2024 earnings at ($0.09) EPS, Q1 2025 earnings at ($0.09) EPS and FY2025 earnings at ($0.34) EPS.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of Oncolytics Biotech in a research report on Thursday.

Oncolytics Biotech Price Performance

Shares of ONCY stock opened at $0.98 on Friday. Oncolytics Biotech has a 1-year low of $0.84 and a 1-year high of $1.75. The stock has a market capitalization of $75.53 million, a PE ratio of -3.63 and a beta of 1.69. The business has a 50-day moving average of $1.09 and a 200 day moving average of $1.06.

Hedge Funds Weigh In On Oncolytics Biotech

An institutional investor recently bought a new position in Oncolytics Biotech stock. Virtu Financial LLC purchased a new stake in shares of Oncolytics Biotech Inc. (NASDAQ:ONCY) in the first quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 51,889 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 0.07% of Oncolytics Biotech at the end of the most recent reporting period. Hedge funds and other institutional investors own 6.82% of the company’s stock.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.